The poor performance of EGFL6 in various cancers, including nasopharyngeal carcinoma (Zhu et al., 2018), lung adenocarcinoma (Chang et al., 2018), ovarian cancer (Bai et al., 2016), etc. may be associated with its remarkable immunosuppressive effect in the tumor immune microenvironment. This evidence concerns the gene EGFL6 and ovarian carcinoma.